JP2009538916A - 志賀毒素関連病状を治療するための方法、組成物、およびキット - Google Patents

志賀毒素関連病状を治療するための方法、組成物、およびキット Download PDF

Info

Publication number
JP2009538916A
JP2009538916A JP2009513264A JP2009513264A JP2009538916A JP 2009538916 A JP2009538916 A JP 2009538916A JP 2009513264 A JP2009513264 A JP 2009513264A JP 2009513264 A JP2009513264 A JP 2009513264A JP 2009538916 A JP2009538916 A JP 2009538916A
Authority
JP
Japan
Prior art keywords
antibody
chimeric anti
stx2
stx1
chimeric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009513264A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009538916A5 (https=
Inventor
マーク リビエール
マリアム メヘラーン
クレア トゥーニング ロバーソン
アリソン オブライエン
アンゲラ メルトン−チェルサー
ジャニク サム−パン
Original Assignee
タリオン ファーマシューティカルズ インコーポレーテッド
ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by タリオン ファーマシューティカルズ インコーポレーテッド, ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド filed Critical タリオン ファーマシューティカルズ インコーポレーテッド
Publication of JP2009538916A publication Critical patent/JP2009538916A/ja
Publication of JP2009538916A5 publication Critical patent/JP2009538916A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1228—Enterobacterales (O), e.g. Citrobacter (G), Serratia (G), Proteus (G), Providencia (G), Morganella (G) or Yersinia (G)
    • C07K16/1232—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2009513264A 2006-05-31 2007-05-31 志賀毒素関連病状を治療するための方法、組成物、およびキット Pending JP2009538916A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80946406P 2006-05-31 2006-05-31
PCT/US2007/012797 WO2007143004A2 (en) 2006-05-31 2007-05-31 Methods, compositions, and kits for treating shiga toxin associated conditions

Publications (2)

Publication Number Publication Date
JP2009538916A true JP2009538916A (ja) 2009-11-12
JP2009538916A5 JP2009538916A5 (https=) 2011-05-12

Family

ID=38802032

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009513264A Pending JP2009538916A (ja) 2006-05-31 2007-05-31 志賀毒素関連病状を治療するための方法、組成物、およびキット

Country Status (6)

Country Link
US (1) US20120195891A1 (https=)
EP (2) EP2545936A3 (https=)
JP (1) JP2009538916A (https=)
AU (1) AU2007254950A1 (https=)
CA (1) CA2652999A1 (https=)
WO (1) WO2007143004A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010085539A1 (en) 2009-01-23 2010-07-29 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods and compositions based on shiga toxin type 2 protein
US8821879B2 (en) 2009-09-04 2014-09-02 Xoma Technology Ltd. Anti-botulism antibody coformulations
IL301603A (en) 2011-10-14 2023-05-01 Genentech Inc Pertuzumab, trastuzumab, docetaxel and carboplatin for use in the preoperative treatment of a patient
US20130195851A1 (en) * 2011-12-23 2013-08-01 Genentech, Inc. Articles of manufacture and methods for co-administration of antibodies
PT3589661T (pt) 2017-03-02 2024-01-29 Genentech Inc Tratamento com adjuvante de cancro da mama positivo para her2
RU2732155C1 (ru) * 2019-09-24 2020-09-11 Открытое акционерное общество "Всероссийский научный Центр молекулярной диагностики и лечения" (ОАО ВНЦМДЛ) Гуманизированное антитело или его антигенсвязывающий фрагмент (Fab) против шига-токсинов первого и/или второго типов (варианты), композиция для лечения токсических состояний, вызванных энтерогеморрагической кишечной палочкой, содержащая указанные антитела и/или Fab

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003521219A (ja) * 1997-12-23 2003-07-15 スティンソン，ジェフリー，エル． 志賀毒素誘発性疾患を防御するヒト化モノクローナル抗体
WO2006030883A1 (ja) * 2004-09-17 2006-03-23 Hamamatsu Foundation For Science And Technology Promotion モノクローナル抗体の製造方法
JP2009527226A (ja) * 2006-02-16 2009-07-30 ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド 志賀トキソイドキメラタンパク質

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003521219A (ja) * 1997-12-23 2003-07-15 スティンソン，ジェフリー，エル． 志賀毒素誘発性疾患を防御するヒト化モノクローナル抗体
WO2006030883A1 (ja) * 2004-09-17 2006-03-23 Hamamatsu Foundation For Science And Technology Promotion モノクローナル抗体の製造方法
JP2009527226A (ja) * 2006-02-16 2009-07-30 ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド 志賀トキソイドキメラタンパク質

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CSNC200901186020; 日本臨牀 Ｖｏｌ．６０, 2002, ｐｐ．５４５-５０ *
JPN6012037961; 日本臨牀 Ｖｏｌ．６０, 2002, ｐｐ．５４５-５０ *
JPN6012037963; Ｖａｃｃｉｎｅ Ｖｏｌ．２４, 20060220, ｐｐ．１１４２-８ *

Also Published As

Publication number Publication date
EP2545936A2 (en) 2013-01-16
US20120195891A1 (en) 2012-08-02
EP2035037A4 (en) 2010-03-31
WO2007143004A2 (en) 2007-12-13
EP2035037A2 (en) 2009-03-18
CA2652999A1 (en) 2007-12-13
AU2007254950A1 (en) 2007-12-13
WO2007143004A3 (en) 2008-03-27
EP2545936A3 (en) 2013-02-20

Similar Documents

Publication Publication Date Title
US11447543B2 (en) Antibodies to S. aureus surface determinants
JPH10505358A (ja) クロストリジウム・ディフィシル関連疾患の治療処置
JP2009538916A (ja) 志賀毒素関連病状を治療するための方法、組成物、およびキット
WO2015100409A2 (en) Methods, compositions and kits for treating a subject using a recombinant neutralizing binding protein
WO2011147984A1 (en) Anti-cd160 specific antibodies for the treatment of eye disorders based on neoangiogenesis
ES2155450T5 (es) Anticuerpos opsonicos fuertemente reactivos, que reaccionan a los antigenos comunes de los staphylococcus.
JP2001501579A (ja) 抗体の産生、及び抗体を含む医療的使用
JP2002534479A (ja) ニューロトロフィンおよびそのアナログを使用する、胃腸の低運動性障害の処置方法
JP7558306B2 (ja) 疼痛の治療における使用のためのＴＧＦ－α及びエピレグリンに結合する抗体
CN109414502A (zh) 治疗炎症性肠病的方法
US20050226872A1 (en) Use of cd25 binding molecules in the treatmnet of inflammatory diseases of the gastrointestinal tract
JP2002513398A (ja) フィブロネクチン結合タンパク質組成物および使用法
JP2003528890A5 (https=)
US20090258010A1 (en) Methods, compositions, and kits for treating shiga toxin associated conditions
CN113474363A (zh) 用于降低体重和/或减少食物摄取量的gdf15类似物和方法
JP2023539047A (ja) 造血幹細胞移植関連血栓性微小血管症（ｈｓｃｔ－ｔｍａ）を処置するための抗ｃ５抗体の用量及び投与
CA2486147A1 (en) Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies
JP2003517445A (ja) 毒性ショック症候群および敗血症性ショックの兆候を減少させるのに有用なペプチド
Kappelman et al. 1044 Costs of Treatment of Crohn's Disease and Ulcerative Colitis in US Children and Adults
HK1215452B (zh) 金黃色葡萄球菌表面決定簇的抗體

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100511

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100511

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110316

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120723

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121005

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121015

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130314